Research programme: depressive disorder and dysuria therapeutics - Alvogen KoreaAlternative Names: KW 21072; KW 21097
Latest Information Update: 01 Jun 2016
At a glance
- Originator KunWha Pharmaceutical
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Depressive disorders; Dysuria
Most Recent Events
- 01 Jun 2015 Early research in Dysuria in South Korea (PO) before June 2015
- 01 Jun 2015 Early research in Depressive disorders in South Korea (PO) before June 2015